Trial Profile
A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Methotrexate; Pegfilgrastim; Prednisone; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms IRiC
- 15 Jun 2023 Results assessing the safety and efficacy of ibrutinib-R-mini-CHOP in very elderly patients with newly diagnosed diffuse large B cell lymphoma, presented at the 28th Congress of the European Haematology Association.
- 02 Jun 2023 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Primary endpoint (efficacy) has not been met, as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.